Diazepam (Valium)

Small molecule

Approved / Phase 4GABA-A receptorNo featureable registry evidence
Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Every registered study for this drug was reviewed, and none was selected as featured evidence for its approved use, so its Featured trials section is empty.

Also approved (1)
US
  • Management of anxiety disorders, or short-term relief of the symptoms of anxiety
Product first approved 1963Outside this platform's coverageFDA label

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (3)
Epilepsy
NCT00004297 · National Institute of Neurological Disorders and Stroke (NINDS)
1995-11 – 1999-02 · Status Epilepticus
What this study did
Other / comorbidity
NCT06293989 · University of Monastir
2024-05-01 – 2026-03-30 · Vertigo, Peripheral
What this study did
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
Phase 2/3 (4)
Other / comorbidity
NCT03825809 · Henry Ford Health System
2019-01-22 – 2020-05-20 · Narcotic Use
What this study did
NCT03818932 · Henry Ford Health System
2019-01-22 – 2020-05-20 · Anterior Cruciate Ligament Injury
What this study did
NCT02646124 · Montefiore Medical Center
2015-06 – 2016-05 · Low Back Pain
What this study did
NCT02935972 · Assiut University
2013-11 – 2015-01 · Pain Relief During Prostate Biopsy
What this study did
Phase 2 (6)
Epilepsy
NCT01417078 · Acorda Therapeutics
2011-09 – 2013-03 · Epilepsy
What this study did
NCT00326612 · University of Utah
2006-06 – 2008-12 · Seizures
What this study did
Other / comorbidity
NCT03818919 · Henry Ford Health System
2019-01-22 – 2020-12-31 · Rotator Cuff Tear
What this study did
NCT01938092 · Raymond Foster
2013-09 – 2017-07 · Pelvic Floor Disorders, Pelvic Pain
What this study did
NCT02232035 · Navy General Hospital, Beijing
2014-09 – 2015-09 · Pain, Prolonged Labour
What this study did
NCT01790555 · Radboud University Medical Center
2013-07 – 2014-04 · Pain
What this study did
Phase 1/2 (1)
Epilepsy
NCT05361447 · Mayo Clinic
2023-01-11 – 2024-12-13 · GAD 65 Antibody-associated Epilepsy
What this study did
Phase 1 (7)
Epilepsy
NCT06271096 · Arooj Khan
2019-11-01 – 2024-01-01 · Seizures
What this study did
NCT01364558 · University of Minnesota
2011-02 – 2011-04 · Epilepsy
What this study did
Other / comorbidity
NCT03820193 · Henry Ford Health System
2019-01-22 – 2021-01-20 · Meniscus Disorder, Narcotic Use
What this study did
NCT05069779 · University of Brasilia
2017-08-01 – 2019-05-20 · Healthy
What this study did
NCT03088306 · Johns Hopkins University
2017-07-01 – 2018-08-31 · Lumbar Spinal Stenosis, Lumbar Spinal Instability, Lumbar Spine Degeneration
What this study did
NCT03165500 · Universidade Estadual Paulista Júlio de Mesquita Filho
2015-12-23 – 2017-05-04 · Anxiety Disease
What this study did
NCT01696825 · Jason Gilleran
2012-10 – 2014-05 · Metabolism, Drug
What this study did
Phase 4 (11)
Epilepsy
NCT04885075 · Shaheed Zulfiqar Ali Bhutto Medical University
2021-05-30 – 2021-11-30 · Seizures
What this study did
NCT03631901 · Tanta University
2017-04-01 – 2018-09-01 · Febrile Seizures
What this study did
Other / comorbidity
NCT04216797 · Swedish Medical Center
2020-01-09 – 2023-02-21 · Levator Ani Syndrome
What this study did
NCT03960671 · Wei Zhao
2018-08-01 – 2022-12-31 · Anxiolytics
What this study did
NCT04198233 · TriHealth Inc.
2020-02-12 – 2022-12 · Postoperative Pain
What this study did
NCT05041985 · Edin Mešanović
2020-01-01 – 2020-12-31 · Whiplash Injuries, Whiplash Injury of Cervical Spine
What this study did
NCT04523935 · Sathbhavana Brain Clinic
2005-12-07 – 2020-08-04 · Cerebral Palsy, Excessive Crying, Pain
What this study did
NCT02494180 · Kwong Wah Hospital
2016-03 – 2018-02 · Infertility
What this study did
NCT01221883 · Hadassah Medical Organization
2013-05 – 2014-12 · Posttraumatic Stress Disorder
What this study did
NCT02177955 · Jimmy Barbalho
2011-01 – 2012-09 · Anxiety
What this study did
NCT01939093 · Chulalongkorn University
2010-03 – 2011-09 · Methamphetamine-induced Psychosis
What this study did
Early phase / not applicable (13)
Other / comorbidity
NCT05860153 · Assiut University
2023-06-01 – 2024-08-01 · Febrile Convulsion
What this study did
NCT04858490 · Centre for Addiction and Mental Health
2021-09-24 – 2023-11-21 · Alcohol Withdrawal
What this study did
NCT05872789 · University of Catania
2020-05-02 – 2023-10-20 · Burning Mouth Syndrome
What this study did
NCT06190483 · King's College London
2019-07-24 – 2023-03-24 · Prodromal Schizophrenia
What this study did
NCT02799641 · TriHealth Inc.
2016-07 – 2022-06 · Contraception
What this study did
NCT03427216 · Dr. John A. Thiel Medical Professional Corporation
2018-09-01 – 2018-12-31 · Pelvic Floor Dyssynergia
What this study did
NCT02659501 · Loma Linda University
2015-07 – 2017-07 · Breast Cancer, Postoperative Pain
What this study did
NCT03996564 · San Antonio Military Medical Center
2016-02-22 – 2016-12-12 · Low Back Pain, Mechanical
What this study did
NCT02242955 · University Hospital, Lille
2014-07 – 2016-07 · Alcoholism
What this study did
NCT01233791 · TriHealth Inc.
2010-11 – 2011-12 · Female Patients With High Tone Pelvic Floor Dysfunction
What this study did
NCT00696033 · University Hospital, Strasbourg, France
2007-07 – 2008-12 · Healthy Subjects
What this study did
NCT00127257 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1999-09 – 2006-06 · Constipation
What this study did
NCT00523185 · Stanford University
2003-05 – 2004-11 · Alcohol Withdrawal
What this study did
Used as active comparator (12)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Other / comorbidity
NCT06103188 · University of Jordan
2023-10-02 – 2023-10-30 · Anxiety, Preoperative Anxiety
What this study did
Phase 2/3 (2)
Epilepsy
NCT02904265 · Mayo Clinic
2016-09 – 2019-07-26 · Landau-Kleffner Syndrome, Status Epilepticus, Electrographic
What this study did
NCT00621478 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2008-02 – 2012-05 · Status Epilepticus
What this study did
Phase 2 (1)
Other / comorbidity
NCT01318369 · Radboud University Medical Center
2011-10 – 2013-05 · Cannabinoid, Tetrahydrocannabinol, Chronic Pancreatitis, Abdominal Pain
What this study did
Phase 1 (1)
Other / comorbidity
NCT01438749 · Hoffmann-La Roche
Run by former owner Roche
2011-10 – 2012-05 · Healthy Volunteer
What this study did
Phase 4 (4)
Other / comorbidity
NCT02078336 · Universitaire Ziekenhuizen KU Leuven
2013-12 – 2025-07 · Dental Care for Disabled
What this study did
NCT04570436 · Viatris Specialty LLC
2021-03-29 – 2022-11-10 · Abuse Potential
What this study did
NCT03246620 · The University of Hong Kong
2017-09-01 – 2018-06-01 · Acute Agitation, Behavioural Emergency
What this study did
NCT01675648 · Institute of Mental Health, Singapore
2012-08 – 2015-07 · Opiate Dependent Patients Who Are Undergoing Inpatient Detoxification in Singapore
What this study did
Early phase / not applicable (3)
Epilepsy
NCT04364321 · Queen Sirikit National Institute of Child Health
2020-05-13 – 2023-06 · Recurrent Febrile Convulsion
What this study did
Other / comorbidity
NCT03653520 · Avanti Anesthesia
2017-06-28 – 2017-11-04 · Cataract
What this study did
NCT01759706 · Università Vita-Salute San Raffaele
2010-10 – 2013-01 · Pancreatic Neoplasms
What this study did
Appears in other studies (13)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Epilepsy
NCT03428360 · Aquestive Therapeutics
2018-01-23 – 2020-06-25 · Epilepsy
What this study did
NCT00319501 · Pfizer
2006-01 – 2014-07 · Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
What this study did
Phase 2 (5)
Epilepsy
NCT03222349 · Aquestive Therapeutics
2017-08-31 – 2020-03-11 · Epilepsy
What this study did
NCT03179891 · Aquestive Therapeutics
2017-05-25 – 2018-12-21 · Epilepsy
What this study did
NCT02316847 · Acorda Therapeutics
2014-12 – 2016-09 · Epilepsy
What this study did
NCT02474407 · Acorda Therapeutics
2015-06 – 2016-07 · Refractory Epilepsy
What this study did
Other / comorbidity
NCT00121563 · National Institute of Nursing Research (NINR)
2005-07 – 2006-02 · Pain
What this study did
Phase 1/2 (1)
Epilepsy
NCT03953820 · Aquestive Therapeutics
2019-04-13 – 2019-07-31 · Epilepsy
What this study did
Phase 1 (2)
Other / comorbidity
NCT07020988 · UCB Biopharma SRL
2025-06-12 – 2026-01-21 · Healthy Participants
What this study did
NCT02663999 · Acorda Therapeutics
2016-01 – 2016-06 · Healthy
What this study did
Phase 4 (3)
Epilepsy
NCT05273398 · University of Cincinnati
2022-03-01 – 2022-11-10 · Epilepsies, Partial
What this study did
Other / comorbidity
NCT03293017 · Universitair Ziekenhuis Brussel
2016-02-01 – 2022-02-01 · Alcohol Use Disorder, Alcohol Withdrawal
What this study did
NCT03877120 · Centro Medico Nacional La Raza, IMSS
2017-11-01 – 2018-08-31 · Alcohol Withdrawal Delirium
What this study did

Competitive landscape

This mechanism is crowded: 14 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Epilepsy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Diazepam (Valium): this drugApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
BrivaracetamApprovedSmall moleculeSynaptic vesicle glycoprotein 2A (SV2A)Partial signalNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidPartial signal
NCT02544763: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1)
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
CarbamazepineApprovedSmall moleculeSodium channelsnot yet gradedNo reviewed efficacy summary in this indication
Cenobamate (Xcopri)ApprovedSmall moleculeSodium channels + GABA-A receptorsWeak signal
NCT03678753: USA and Rest of World (RoW): Percent Change in PGTC Seizure Frequency Per 28 Days During the Double-blind Treatment Period Relative to Baseline. (Baseline and 22-week Double-blind Treatment Period.): Cenobamate -71.9% (range -100 to 273) vs Placebo -39.61% (range -100 to 211.8)
NCT04557085: Median percent change in 28-day focal seizure frequency, 6-week maintenance phase: placebo -25.9% vs cenobamate 100 mg -42.6%, 200 mg -78.3%, 400 mg -100% (all p<.001; Epilepsia 2026)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
NCT01160770: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment (Baseline to month 36): Clobazam 92.3 percentage of drop seizures (range -588 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Diastat)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valtoco)ApprovedSmall moleculeGABA-A receptorWeak signalFeatured results are non-efficacy only in this race
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Eslicarbazepine Acetate (Aptiom)ApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT02484001: Primary endpoint (retention time / probability of ESL withdrawal) at 24 months: 0.0638 (95% CI 0.0292-0.1366) in the ESL/ESL group vs 0.0472 (95% CI 0.0180-0.1210) in the CBZ-CR/ESL group
NCT00988156: Change From Baseline in Seizure Frequency (Baseline up to Visit 7): Esl (BIA 2-093) 36.6 seizures/month (Standard Deviation 72.47) vs Placebo 62 seizures/month (Standard Deviation 186.19) missed
EthosuximideApprovedSmall moleculeT-type calcium channelReliable signal
NCT00088452: Freedom from treatment failure at 16–20 weeks: 81/154 ethosuximide vs 43/146 lamotrigine, odds ratio 2.66 (95% CI 1.65–4.28; p<0.001); ethosuximide vs valproic acid: 81/154 vs 85/146, with no direct statistical comparison posted.
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Reliable signal
NCT01713946: Primary 1, response rate (≥50% seizure-frequency reduction) in the maintenance period: placebo 15.1%, low-exposure everolimus 28.2% (p=0.0077), high-exposure everolimus 40.0% (p<0.0001), met for both doses. Primary 2, median percentage reduction in seizure frequency: placebo 14.9%, low exposure 29.3% (p=0.0028), high exposure 39.6% (p<0.0001), met for both doses.
FelbamateApprovedSmall moleculeNMDA receptor (glycine site, antagonist)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
FosphenytoinApprovedSmall moleculeVoltage-gated sodium channelPartial signalNo reviewed efficacy summary in this indication
GabapentinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsPartial signal
NCT00007670: VA Cooperative Study 428 (18 centers, 593 elderly patients with new-onset seizures), matching this trial's title/sponsor/design exactly. Primary endpoint (12-month trial retention): early-termination rates were gabapentin 51%, lamotrigine 44.2%, carbamazepine 64.5% (p=0.0002); gabapentin significantly outperformed carbamazepine (p=0.008) but was not shown superior to lamotrigine. Seizure control was similar across all three arms.
NCT00603473: Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures (12 weeks): Gabapentin -0.158 ratio (95% CI -0.221 to -0.096)
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT04391569: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741)
NCT01963208: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period (Baseline and Week 14): Double Blind: Cohort 2 - Ganaxolone -21.28 Percent change (95% CI -29.6 to -14.29) | Double Blind: Cohort 2 - Placebo -10.25 Percent change (95% CI -20.14 to -1.28) missed
Lacosamide (Vimpat)ApprovedSmall moleculeVoltage-gated sodium channelsReliable signal
NCT00136019: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001).
NCT02408523: Primary endpoint, time to second PGTC seizure over 24 weeks: hazard ratio 0.540 (95% CI 0.377 to 0.774), p<0.001, lacosamide vs placebo (CT.gov posted results; 49 vs 76 patients with a second PGTC seizure).
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00088452: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 missed
NCT01431976: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) (Week 12 of the Maintenance Phase (up to Study Week 50)): Lamotrigine 7/20
Levetiracetam (Elepsia XR)
ApprovedUS marketing discontinued
Small moleculeSynaptic vesicle glycoprotein 2A (SV2A)not yet gradedNo reviewed efficacy summary in this indication
Levetiracetam (Keppra XR)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signalFeatured results are non-efficacy only in this race
Levetiracetam (Keppra)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signal
NCT00150709: Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): N159 PBO/LEV -66.4 percentage of change (IQR -90 to -22.3) | N159 LEV/LEV -47.8 percentage of change (IQR -76.2 to -25.4) | N01010+N151 LEV/LEV -66.4 percentage of change (IQR -93.6 to -5.6)
NCT00615615: Partial-onset seizure frequency per week during the 14-week treatment period (primary endpoint): 26.8% greater reduction with levetiracetam vs placebo (p=0.0002, 95% CI 14.0-37.6%); 50%-responder rate 44.6% (45/101) LEV vs 19.6% (19/97) placebo (p=0.0002).
LorazepamApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Midazolam (Nayzilam)ApprovedSmall moleculeGABA-A receptor, GABA-A receptor (benzodiazepine site)Reliable signal
NCT01390220: Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67
NCT01999777: Number of Participants That Were Seizure-free (6 hours): USL261 17/31 vs Placebo 12/31 missed
Oxcarbazepine (Oxtellar XR)ApprovedSmall moleculeVoltage-gated sodium channelPartial signalFeatured results are non-efficacy only in this race
Oxcarbazepine (Trileptal)ApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00050934: Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047.
Perampanel (Fycompa)ApprovedSmall moleculeAMPA receptor (antagonist)Weak signal
NCT01393743: Core study: median percent change in PGTC seizure frequency per 28 days, perampanel -76.5% vs placebo -38.4%, median difference -30.8 (95% CI -45.5 to -15.2), p=0.0001; 50% responder rate in maintenance 64.2% vs 39.5%, p=0.0019 (n=81 each) (CT.gov posted results).
NCT00699582: Median percent change in 28-day seizure frequency: placebo -9.7%, perampanel 8 mg -30.5% (p<0.001), 12 mg -17.6% (p=0.011); 50% responder rate 14.7%, 33.3% (p=0.002) and 33.9% (p<0.001) (Study 305, Epilepsia 2013).
Phenobarbital Sodium Injection (Sezaby)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
PhenytoinApprovedSmall moleculeVoltage-gated sodium channelsnot yet gradedNo reviewed efficacy summary in this indication
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsWeak signal
NCT01747915: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Pregabalin 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day 1.17 Seizure per 28 days (Standard Error 0.097) | Pregabalin 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day 1.13 Seizure per 28 days (Standard Error 0.095) vs Placebo 1.14 Seizure per 28 days (Standard Error 0.098) missed
PrimidoneApprovedSmall molecule—not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
RufinamideApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT00334958: Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis).
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
TiagabineApprovedSmall moleculeGABA transporter (uptake carrier)not yet gradedNo reviewed efficacy summary in this indication
Topiramate (Eprontia)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Qudexy XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydraseReliable signal
NCT01142193: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100)
Topiramate (Topamax Sprinkle)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Topamax)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasePartial signal
NCT00113815: Primary endpoint, median % reduction from baseline in daily partial-onset-seizure rate (video-EEG): topiramate 25 mg/kg 20.4% vs placebo 13.1% (p=0.97); 15 mg/kg dose p=0.97 vs placebo; 5 mg/kg dose p=0.91 vs placebo -- no dose significantly better than placebo. missed
NCT00236756: Topiramate add-on in Lennox-Gastaut syndrome: median percentage reduction from baseline in average monthly seizure rate 14.8% with topiramate versus a -5.1% increase with placebo; a >=50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was reached by 33% of the topiramate group versus 8% of the control group.
Topiramate (Trokendi XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Valproate
ApprovedUS marketing discontinued
Small moleculeGABAergic neurotransmissionPartial signal
NCT00004817: Phase III NINDS trial (Temkin et al.): valproate did not reduce early or late post-traumatic seizure rates vs phenytoin control, and showed a trend toward higher mortality (13.4% vs 7.2%). missed
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)Partial signal
NCT02849457: Cognitive Assessment Scores and Developmental Impact (24 months): Delayed Vigabatrin (Placebo) 83.9 score on a scale ± 17.3 vs Early Vigabatrin 80.9 score on a scale ± 15.6 vs Watchful Waiting (Control Group) 97.3 score on a scale ± 16.9 vs Watchful Waiting (Open Label Vigabatrin) 85.0 score on a scale ± 21.6; p=0.8681 (Delayed Vigabatrin (Placebo) vs Early Vigabatrin) missed
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Zonisamide (Zonegran)ApprovedSmall moleculeVoltage-gated sodium channelsWeak signalFeatured results are non-efficacy only in this race
Zonisamide (Zonisade)ApprovedSmall moleculeVoltage-gated sodium and T-type calcium channelsnot yet gradedNo reviewed efficacy summary in this indication
AzetukalnerPhase 3Small moleculeKv7 potassium channelReliable signal
NCT05614063: Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4%
BexicaserinPhase 3Small moleculeSerotonin 5-HT2C receptor (agonist)Partial signal
NCT05364021: Primary endpoint, median percentage change in countable motor seizures over the treatment period: bexicaserin -59.8% (n=35) vs placebo -17.4% (n=9), difference 42.4%, p = .0538 (not statistically significant) (PACIFIC, Epilepsia 2026). missed
CarisbamatePhase 3Small moleculeVoltage-gated sodium channelPartial signal
NCT00425282: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results).
NCT00433667: Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). missed
Clemizole (EPX-100)Phase 3Small moleculeHistamine H1 receptor, Serotonin receptors (5-HT)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Libervant)Phase 3Small moleculeGABA-A receptorWeak signalFeatured results are safety only in this race
ElsunersenPhase 3RNA / oligonucleotideSCN2A (antisense knockdown)Partial signal
NCT05737784: Part A (randomized 3:1, sham-controlled, 9 patients): 77% placebo-adjusted seizure reduction from baseline (p=0.015) (Praxis, 2026-04-06).
KH607
Phase 3(overall)
Small moleculeGABA-A receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
RAP-219Phase 3Small moleculeAMPA receptor (TARP γ8-dependent)Weak signal
NCT06377930: Primary endpoint met: 85.2% of patients achieved ≥30% reduction in long episodes (LEs) from baseline (p<0.0001); 72.0% achieved ≥50% reduction in clinical seizures (p<0.0001)
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
Staccato AlprazolamPhase 3Small moleculeGABA-A receptorReliable signal
NCT03478982: 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8)
VormatriginePhase 3Small moleculeVoltage-gated sodium channel (NaV1.2 / NaV1.6)Partial signal
NCT06999902: Primary success measure (reduction in focal seizure frequency over 12 weeks versus placebo) not met, per Praxis; the secondary 50% responder rate was met. The company disclosed no numbers. missed
YCJ-01Phase 3BotanicalCannabinoids (full-spectrum cannabis extract)not yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (JZP926)Phase 2/3Small moleculeCannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55, cannabinoidnot yet gradedNo reviewed efficacy summary in this indication
OpakalimPhase 2/3Small moleculeKv7 potassium channelWeak signal
NCT06425159: Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26).
ABS-1230Phase 2Small moleculeKCNT1 (KNa1.1/Slack) channelnot yet gradedNo reviewed efficacy summary in this indication
AV078Phase 2Small moleculemTORC1 (mammalian target of rapamycin complex 1) (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
BMB-101Phase 2Small moleculeSerotonin 5-HT2C receptor (biased agonist)not yet gradedNo reviewed efficacy summary in this indication
CB03-154Phase 2Small moleculeKCNQ2/3 (Kv7.2/7.3) potassium channel (opener)not yet gradedNo reviewed efficacy summary in this indication
GlyphAllo (allopregnanolone Prodrug) (SPT-300)
Phase 2(overall)
Small moleculeGABA-A receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
HS-10353
Phase 2(overall)
Small moleculeGABA-A receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Huperzine A (SPN-817)Phase 2Small moleculeAcetylcholinesteraseWeak signal
NCT03156439: Participants were given the experimental treatment twice a day, with the dose increased every two to three days until a maximum daily dose of 2.5 mg was reached. Participants tolerated the treatment well, with mild to moderate, transient and non-dose-limiting adverse events.
NPT2042Phase 2Small moleculeNKCC1Partial signalNo reviewed efficacy summary in this indication
AMT-260Phase 1/2Gene therapy / editingGRIK2 (GluK2-containing kainate receptor)not yet gradedNo reviewed efficacy summary in this indication
ETX101Phase 1/2Gene therapy / editingSCN1A (transcriptional upregulation)not yet gradedNo reviewed efficacy summary in this indication
ION337Phase 1/2RNA / oligonucleotideSCN1A mRNAnot yet gradedNo reviewed efficacy summary in this indication
S230815Phase 1/2RNA / oligonucleotideKCNT1 mRNAnot yet gradedNo reviewed efficacy summary in this indication
iQ-007Phase 1Small moleculeEAAT2 (glutamate transporter, positive allosteric modulator)not yet gradedNo reviewed efficacy summary in this indication
Remimazolam
Phase 1(overall)
Small moleculeGABA-A receptor
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 74 furthest-along competitors are listed; 3 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

1 further pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

No upcoming readouts on record for this asset.